title: [Gemtuzumab ozogamicin for treatment of acute myeloid leukemia].
abstract: Gemtuzumab ozogamicin (GO) is a humanized monoclonal antibody anti-CD33 conjugated with calicheamicin and was indicated for acute myeloid leukemia (AML) patients. It was initially approved in 2000 by FDA thank to promising results from a phase II trial including elderly relapsing AML patients. Numerous studies evaluated this treatment as salvage and frontline therapy in various regimens including associations with intensive chemotherapy. Based on the results from a randomized phase III trial, this agent was withdrawal because of no evidence for its benefit in terms of survival associated with excessive toxicity. Other phase III trials were then reported and show potentially better efficacy/toxicity profile. We review here the results of main trials interesting this agent, which is so far only available in a compassionate ATU program in France for the treatment of relapsing CD33+ AML patients.
authors.affiliation: CHU Estaing Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand cedex 01, France.
authors.forename: Thibault
authors.initials: T
authors.lastname: Brotelle
authors.affiliation: CHU Estaing Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand cedex 01, France.
authors.forename: Richard
authors.initials: R
authors.lastname: Lemal
authors.affiliation: CHU Estaing Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand cedex 01, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Moluçon-Chabrot
authors.affiliation: CHU Estaing Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand cedex 01, France, Université d'Auvergne, EA7283, CIC501, BP 10448, 63000 Clermont-Ferrand, France.
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
authors.affiliation: CHU Nantes, service d'hématologie clinique, 44093 Nantes, France.
authors.forename: Jacques
authors.initials: J
authors.lastname: Delaunay
authors.affiliation: CHU Estaing Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand cedex 01, France, Université d'Auvergne, EA7283, CIC501, BP 10448, 63000 Clermont-Ferrand, France.
authors.forename: Romain
authors.initials: R
authors.lastname: Guièze
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D057176:Compassionate Use Trials; D005602:France; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic
chemical_list: D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000079982:Gemtuzumab
keywords: CD33; acute myeloid leukemia; gemtuzumab ozogamicin; monoclonal antibodies
vernacular_title: Intérêt du gemtuzumab ozogamicin dans les leucémies aiguës myéloïdes.